These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36810039)

  • 1. Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance.
    Bo Q; Wang X; Liu X; Sang H; Xun Z; Zhang R; Yang X; Deng H; Li K; Chen J; Sun M; Zhao G; Liu X; Cai D; Zhan G; Li J; Li H; Wang G
    BMC Psychiatry; 2023 Feb; 23(1):115. PubMed ID: 36810039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance.
    Wu H; Wang X; Liu X; Sang H; Bo Q; Yang X; Xun Z; Li K; Zhang R; Sun M; Cai D; Deng H; Zhao G; Li J; Liu X; Zhan G; Chen J
    Front Psychiatry; 2022; 13():935769. PubMed ID: 36061293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.
    Inoue Y; Tsuchimori K; Nakamura H
    J Pharmacol Sci; 2021 Jan; 145(1):42-51. PubMed ID: 33357778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of oral medium to high dose blonanserin in patients with schizophrenia: subgroup analysis from a prospective, multicenter, post-marketing surveillance study in mainland China.
    Yang Y; Ge H; Wang X; Liu X; Li K; Wang G; Yang X; Deng H; Sun M; Zhang R; Chen J; Cai D; Sang H; Liu X; Zhan G; Zhao G; Li H; Xun Z
    Ann Gen Psychiatry; 2023 Oct; 22(1):37. PubMed ID: 37803378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
    Garcia E; Robert M; Peris F; Nakamura H; Sato N; Terazawa Y
    CNS Drugs; 2009; 23(7):615-25. PubMed ID: 19552488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
    Iwata N; Ishigooka J; Naoi I; Matsumoto M; Kanamori Y; Nakamura H; Higuchi T
    CNS Drugs; 2020 Jan; 34(1):103-116. PubMed ID: 31883082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
    Li H; Yao C; Shi J; Yang F; Qi S; Wang L; Zhang H; Li J; Wang C; Wang C; Liu C; Li L; Wang Q; Li K; Luo X; Gu N
    J Psychiatr Res; 2015 Oct; 69():102-9. PubMed ID: 26343601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
    Kawabe K; Horiuchi F; Ueno S
    Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance.
    Wei YM; Wang XJ; Yang XD; Wang CS; Wang LL; Xu XY; Zhao GJ; Li B; Zhu DM; Wu Q; Shen YF
    World J Psychiatry; 2023 Nov; 13(11):937-948. PubMed ID: 38073894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study.
    Saito T; Hyodo Y; Sakaguchi R; Nakamura H; Ishigooka J
    J Child Adolesc Psychopharmacol; 2022 Feb; 32(1):24-35. PubMed ID: 34612724
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study.
    Woo YS; Yoon BH; Jeon BH; Seo JS; Nam B; Lee SY; Jae YM; Jang SH; Eun HJ; Won SH; Lee K; Lee J; Bahk WM
    Clin Psychopharmacol Neurosci; 2019 Aug; 17(3):423-431. PubMed ID: 31352709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study.
    Ohi K; Takai K; Kuramitsu A; Sugiyama S; Shioiri T
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 113():110470. PubMed ID: 34740708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study.
    Yu W; Lei L; Yu Y; Li Y; Shen Y; Li H
    Hum Psychopharmacol; 2020 Jan; 35(1):e2717. PubMed ID: 31837240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
    Iwata N; Ishigooka J; Kim WH; Yoon BH; Lin SK; Sulaiman AH; Cosca R; Wang L; Suchkov Y; Agarkov A; Watabe K; Matsui T; Sato T; Inoue Y; Higuchi T; Correll CU; Kane JM
    Schizophr Res; 2020 Jan; 215():408-415. PubMed ID: 31471246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sertindole for schizophrenia.
    Lewis R; Bagnall AM; Leitner M
    Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD001715. PubMed ID: 16034864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blonanserin: a review of its use in the management of schizophrenia.
    Deeks ED; Keating GM
    CNS Drugs; 2010 Jan; 24(1):65-84. PubMed ID: 20030420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.
    Ninomiya Y; Miyamoto S; Tenjin T; Ogino S; Miyake N; Kaneda Y; Sumiyoshi T; Yamaguchi N
    Psychiatry Clin Neurosci; 2014 Dec; 68(12):841-849. PubMed ID: 24835911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis.
    Tachibana M; Niitsu T; Watanabe M; Hashimoto T; Kanahara N; Ishikawa M; Iyo M
    Asian J Psychiatr; 2016 Dec; 24():28-32. PubMed ID: 27931902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial.
    Pu C; Lei L; Yang F; Deng H; Sheng J; Liu Z; Hu S; Wang L; Wu B; Bo Q; Inoue Y; Yu X
    BMJ Open; 2022 Apr; 12(4):e054079. PubMed ID: 35443947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of blonanserin versus risperidone in the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Deng SW; Xu Q; Jiang WL; Hong B; Li BH; Sun DW; Yang HB
    BMC Psychiatry; 2023 Oct; 23(1):740. PubMed ID: 37821875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.